2017
Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era?
Justice AC, Erlandson KM, Hunt P, Landay A, Miotti P, Tracy RP. Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era? The Journal Of Infectious Diseases 2017, 217: 521-528. PMID: 29165684, PMCID: PMC5853399, DOI: 10.1093/infdis/jix586.Peer-Reviewed Original ResearchConceptsHIV infectionLong-term treatment toxicityAntiretroviral therapy eraChronic HIV infectionLow-level inflammationT-cell countsForms of cancerART initiationTherapy eraTreatment toxicityImmune dysfunctionRenal diseaseLiver diseaseChronic inflammationIntervention trialsClinical managementNeurocognitive declineCardiovascular diseaseClinical trialistsUninfected individualsRNA suppressionHIV researchWeight gainTranslational scientistsBiomarkers
2008
Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.
Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Annals Of Internal Medicine 2008, 148: 178-85. PMID: 18252681, PMCID: PMC3124094, DOI: 10.7326/0003-4819-148-3-200802050-00004.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyViral loadHIV treatmentEarly treatmentEarly initiationLife expectancyVeterans Aging Cohort StudyChronic HIV infectionCombination antiretroviral therapyEarly treatment initiationAging Cohort StudyTherapy-related toxicityAge 40 yearsQuality-adjusted life expectancyAge 30 yearsBase-case analysisCohort studyHIV infectionTreatment initiationCopies/Current recommendationsLate treatmentImportant harmsTherapyTreatment